March 31, 2023 01:37 PM EDT
Pharma
Marketing

Phar­ma in­dus­try rep­u­ta­tion scores pos­i­tive bump from in­sulin pric­ing news — Har­ris Poll

Beth Snyder Bulik

Senior Editor

In­sulin drug prices and out-of-pock­et costs have been hot top­ics — and a drag on phar­ma in­dus­try rep­u­ta­tion — for years. But now re­cent news from a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times